NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name (Descending) | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
63187-0265-30 | 63187-0265 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Nov. 3, 2014 | In Use | |
63187-0265-60 | 63187-0265 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | July 3, 2017 | In Use | |
63187-0265-90 | 63187-0265 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | July 3, 2017 | In Use | |
61919-0733-90 | 61919-0733 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Jan. 18, 2019 | In Use | |
70518-1704-00 | 70518-1704 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Nov. 30, 2018 | Dec. 2, 2019 | In Use |
70518-1704-01 | 70518-1704 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Feb. 19, 2024 | In Use | |
70518-3616-00 | 70518-3616 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Jan. 18, 2023 | In Use | |
70518-3616-01 | 70518-3616 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Feb. 10, 2023 | In Use | |
70518-3616-03 | 70518-3616 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | May 10, 2023 | In Use | |
70518-3616-04 | 70518-3616 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Jan. 25, 2024 | In Use | |
72189-0542-90 | 72189-0542 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | March 11, 2024 | In Use | |
00078-0249-15 | 00078-0249 | Letrozole | Femara | 2.5 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | July 31, 1997 | In Use | ||
54868-4151-00 | 54868-4151 | Letrozole | Femara | 2.5 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | Feb. 10, 2005 | In Use | ||
00310-0720-10 | 00310-0720 | Fulvestrant | Faslodex | 50.0 mg/mL | Hormonal Therapy | Estrogen Receptor Antagonist | Intramuscular | Nov. 1, 2010 | In Use | ||
00310-0720-25 | 00310-0720 | Fulvestrant | Faslodex | 50.0 mg/mL | Hormonal Therapy | Estrogen Receptor Antagonist | Intramuscular | Nov. 1, 2010 | Sept. 21, 2010 | In Use | |
00310-0720-50 | 00310-0720 | Fulvestrant | Faslodex | 50.0 mg/mL | Hormonal Therapy | Estrogen Receptor Antagonist | Intramuscular | May 20, 2002 | Oct. 31, 2015 | In Use | |
00078-0651-06 | 00078-0651 | Panobinostat | Farydak | 15.0 mg/1 | Chemotherapy | Enzyme Inhibitor | HDAC | Oral | Feb. 23, 2015 | Dec. 31, 2022 | No Longer Used |
00078-0652-06 | 00078-0652 | Panobinostat | Farydak | 20.0 mg/1 | Chemotherapy | Enzyme Inhibitor | HDAC | Oral | Feb. 23, 2015 | Dec. 31, 2022 | No Longer Used |
00078-0650-06 | 00078-0650 | Panobinostat | Farydak | 10.0 mg/1 | Chemotherapy | Enzyme Inhibitor | HDAC | Oral | Feb. 23, 2015 | Jan. 31, 2023 | No Longer Used |
11399-0005-01 | 11399-0005 | Toremifene Citrate | Fareston | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | June 30, 1997 | April 30, 2016 | No Longer Used | |
11399-0005-07 | 11399-0005 | Toremifene Citrate | Fareston | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | June 30, 1997 | April 30, 2016 | No Longer Used | |
11399-0005-30 | 11399-0005 | Toremifene Citrate | Fareston | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | June 30, 1997 | April 30, 2016 | No Longer Used | |
42747-0327-07 | 42747-0327 | Toremifene Citrate | Fareston | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | June 30, 1997 | Oct. 27, 2016 | In Use | |
42747-0327-30 | 42747-0327 | Toremifene Citrate | Fareston | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | June 30, 1997 | In Use | ||
42747-0327-72 | 42747-0327 | Toremifene Citrate | Fareston | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | June 30, 1997 | In Use |
Found 10,000 results in 15 milliseconds — Export these results